115 related articles for article (PubMed ID: 1978943)
1. HER-2/neu oncogene amplification and expression in breast and ovarian cancers.
Press MF; Jones LA; Godolphin W; Edwards CL; Slamon DJ
Prog Clin Biol Res; 1990; 354A():209-21. PubMed ID: 1978943
[No Abstract] [Full Text] [Related]
2. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
3. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
4. Assessing sequential oncogene amplification in human breast cancer.
Janocko LE; Lucke JF; Groft DW; Brown KA; Smith CA; Pollice AA; Singh SG; Yakulis R; Hartsock RJ; Shackney SE
Cytometry; 1995 Sep; 21(1):18-22. PubMed ID: 8529465
[TBL] [Abstract][Full Text] [Related]
5. Risk of breast cancer according to the status of HER-2/neu oncogene amplification.
Huang WY; Newman B; Millikan RC; Conway K; Hulka BS; Schell MJ; Liu ET
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):65-71. PubMed ID: 10667465
[TBL] [Abstract][Full Text] [Related]
6. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
[TBL] [Abstract][Full Text] [Related]
7. Oncogene may be an important prognostic factor in breast cancer and ovarian cancer.
Oncology (Williston Park); 1989 Jun; 3(6):148. PubMed ID: 2641500
[No Abstract] [Full Text] [Related]
8. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract][Full Text] [Related]
9. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
10. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
11. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
12. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population.
Descotes F; Pavy JJ; Adessi GL
Anticancer Res; 1993; 13(1):119-24. PubMed ID: 8097388
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
[TBL] [Abstract][Full Text] [Related]
14. Follow-up study of HER-2/neu amplification in primary breast cancer.
Clark GM; McGuire WL
Cancer Res; 1991 Feb; 51(3):944-8. PubMed ID: 1988136
[TBL] [Abstract][Full Text] [Related]
15. eEF1A2 as a putative oncogene.
Lee MH; Surh YJ
Ann N Y Acad Sci; 2009 Aug; 1171():87-93. PubMed ID: 19723040
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu signal transduction in human breast and ovarian cancer.
Reese DM; Slamon DJ
Stem Cells; 1997; 15(1):1-8. PubMed ID: 9007217
[TBL] [Abstract][Full Text] [Related]
17. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S
Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
[TBL] [Abstract][Full Text] [Related]
18. [Problems in multidisciplinary treatment from the standpoint of clinical characteristics in human cancers].
Kikuchi K; Ueda M; Fujisaki M; Watanabe M; Tsuyuki A; Fujishiro Y; Kitajima M
Nihon Geka Gakkai Zasshi; 1992 Sep; 93(9):948-51. PubMed ID: 1361657
[TBL] [Abstract][Full Text] [Related]
19. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.
Garcia MJ; Pole JC; Chin SF; Teschendorff A; Naderi A; Ozdag H; Vias M; Kranjac T; Subkhankulova T; Paish C; Ellis I; Brenton JD; Edwards PA; Caldas C
Oncogene; 2005 Aug; 24(33):5235-45. PubMed ID: 15897872
[TBL] [Abstract][Full Text] [Related]
20. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]